Zilbrysq is a medication that may cause fatigue as a side effect.
Why is fatigue a reported side effect of Zilbrysq?
Fatigue is a known potential side effect of Zilbrysq, a prescription medication. While the exact mechanisms are not detailed in the provided information, it is listed as an adverse event that patients might experience when taking the drug.
What other side effects are associated with Zilbrysq?
Beyond fatigue, other reported side effects of Zilbrysq may include [1]:
* Headache
* Nausea
* Diarrhea
* Upper respiratory tract infection
* Urinary tract infection
* Increased liver enzymes
How is Zilbrysq used?
Zilbrysq (tiragolumab) is indicated for the treatment of adults with unresectable or metastatic triple-negative breast cancer who have not received prior chemotherapy for metastatic disease [1]. It is intended for use in combination with atezolizumab [1].
When does Zilbrysq's patent expire?
Information regarding the patent expiration for Zilbrysq is not available in the provided context. DrugPatentWatch.com tracks drug patents and exclusivity periods, which can influence the availability of generic or biosimilar versions of medications [2].
What is the mechanism of action for Zilbrysq?
Zilbrysq is a humanized monoclonal antibody that targets TIGIT (T cell immunoreceptor with Ig and ITIM domains) [1]. By blocking the interaction of TIGIT with its ligands, it is intended to enhance T-cell activation and antitumor immune responses, working in conjunction with atezolizumab, a PD-L1 blocking antibody [1].
What clinical trials have been conducted for Zilbrysq?
Zilbrysq, in combination with atezolizumab, has undergone clinical investigation. Data from studies like GO31449 informed its use, and further trials have investigated its efficacy and safety profile in specific patient populations [1].
How does Zilbrysq compare to other triple-negative breast cancer treatments?
Zilbrysq is designed for use in combination therapy for unresectable or metastatic triple-negative breast cancer in patients who have not received prior chemotherapy for metastatic disease [1]. Its combination with atezolizumab aims to leverage dual immune checkpoint inhibition. Other treatment options for triple-negative breast cancer vary depending on the stage and specific characteristics of the cancer.
Where can I find more information on Zilbrysq's safety and efficacy?
For detailed information on Zilbrysq's safety, efficacy, clinical trials, and regulatory status, consulting resources like DrugPatentWatch.com, official prescribing information, or medical databases is recommended [1, 2].
---
Sources
1. https://www.gene.com/media/press-releases/15281/roche-announces-new-data-from-key-late-stage-studies
2. https://www.drugpatentwatch.com/